Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Proactive Investors CEO Series 2018
19 slides from Kazia Therapeutics's conference presentation, Mar 19, 2018
Slide 1: Kazia presentation to Proactive Investors: CEO Series (ASX release)
ASX RELEASE 19 March 2018 KAZIA PRESENTION TO PROACTIVE INVESTORS: CEO SERIES Sydney, 19 March 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide to the market the presentation which will be given in the Proactive I
Slide 2: An emerging oncology developer with two clinical-stage programs
An emerging oncology developer with two clinical-stage programs Proactive Investors CEO Series Sydney & Melbourne 20 & 21 March 2018 ASX: KZA | NASDAQ : KZIA
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe- harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 4: Investment Highlights
Investment Highlights Cancer-focused biotech with two distinct therapies in clinical trials 1 - GDC-0084 entering phase II trial for brain cancer - Cantrixil currently in phase I trial for ovarian cancer 2 Business strategy focused on owning assets at a critical stage in their value life-cycle, deli
Slide 5: Kazia is focused on development of high-potential novel therapies for poorly-served cancers
Kazia is focused on development of high-potential novel therapies for poorly-served cancers Identify Value Build Value Realise Value • Conduct focused clinical trials • Bring in under- • Identify optimal • Partner with big valued assets patient groups pharma for late- from other • Understand safety
Slide 6: A strong team brings international experience in big pharma and early-stage biotech
A strong team brings international experience in big pharma and early-stage biotech Board Scientific Advisory Board Iain Ross Professor Sir Murray Brennan Chairman Emeritus Chairman of Cancer Surgery at Memorial Sloan Kettering Executive and Board roles in pharma Hospital, New York and small biotech
Slide 7: Kazia is listed on ASX and NASDAQ, with a market cap of ~AU$ 27 million
Kazia is listed on ASX and NASDAQ, with a market cap of ~AU$ 27 million Share Price (AU$) KZA As at 31 December 2017 0.80 Current Assets* Debt ~AU$ 14.8 million Nil 0.70 0.60 Market Capitalisation AU$ 27 million 0.50 ASX: KZA Listing NASDAQ: KZIA (1:10 ratio) 0.40 ASX: 0.1% /day Average Daily Volume
Slide 8: Our efforts are attracting increasing attention from media and the investment community
Our efforts are attracting increasing attention from media and the investment community 6
Slide 9: Two clinical programs, with value-driving inflection points providing impactful newsflow during 2018
Two clinical programs, with value-driving inflection points providing impactful newsflow during 2018 ✓ (late March / early April 2018) (early calendar 2019) GDC-0084 Brain-penetrant Read-out from Receipt of PI3K inhibitor, Start of phase II dose Orphan Drug developed to study in first- optimisation
Slide 10: GDC-0084 Phase II Glioblastoma Multiforme
GDC-0084 Phase II Glioblastoma Multiforme 8
Slide 11: Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer
Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung No clear 3-4 months 12-15 cause untreated months Breast or strong risk survival average 14 million factors survival with cancer cases treatment per annum Colon Any age, Five-year Prostate but most survival co
Slide 12: Current standard of care is essentially ineffective in up to 65% of GBM cases
Current standard of care is essentially ineffective in up to 65% of GBM cases Standard of Care Debulking surgery Radiotherapy + Temozolomide (‘Stupp where possible temozolomide maintenance therapy Regimen’) 6 weeks 4w 6 x 28-day cycles Temozolomide is clearly efficacious… …but only in ~35% of patien
Slide 13: There is increasing recognition of the need to find treatment options for patients diagnosed with GBM
There is increasing recognition of the need to find treatment options for patients diagnosed with GBM Growing public attention for brain cancer highlights need for new treatment options • Senator John McCain’s diagnosis in July 2017 highlighted glioblastoma and focused attention on the need for new
Slide 14: The PI3K pathway is central to many types of cancer, and especially to GBM
The PI3K pathway is central to many types of cancer, and especially to GBM PI3K ACTIVATED TUMOUR 85 – 90% of glioblastoma cases GROWTH have PI3K ‘switched on’ PI3K A central biochemical >50% of patients at therapeutic doses (45-65mg) in phase I human trials control achieved ‘stable disease’ mechanis
Slide 15: The PI3K class has been validated by approval of a new therapy in September 2017
The PI3K class has been validated by approval of a new therapy in September 2017 PI3K class further validated by approval of Bayer’s AliqopaTM (copanlisib) for lymphoma in Sept 2017 • Two PI3K inhibitors now successfully brought to market – Zydelig (idelalisib) [Gilead] – Aliqopa (copanlisib) [Bayer
Slide 16: Genentech's phase I clinical study of GDC-0084 established dosing and showed favourable safety
Genentech’s phase I clinical study of GDC-0084 established dosing and showed favourable safety Safety Efficacy Signals • Phase I safety trial conducted by Genentech GDC-0084 • 47 patients enrolled with advanced 40% glioma (grade 3/4); average of Arresting Achieved three prior lines of therapy Tumour
Slide 17: Kazia is about to initiate a phase II clinical trial of GDC-0084 in glioblastoma
Kazia is about to initiate a phase II clinical trial of GDC-0084 in glioblastoma Transfer of IND with US FDA from Genentech and updating ✓ Design of phase II clinical study with input from clinicians ✓ Manufacture of drug substance into capsules for clinical trial use ✓ Engagement of contract resear
Slide 18: Other companies focused on the PI3K pathway have been highly-valued in the market
Other companies focused on the PI3K pathway have been highly-valued in the market Single asset company with one PI3K US$ 130 million inhibitor in phase I human trials Market Cap One PI3K inhibitor in phase II human trials, one other drug in phase III, and US$ 1.2 billion two in animal testing Market
Slide 19: www.kaziatherapeutics.com
www.kaziatherapeutics.com Twitter: @KaziaTx
Kazia Therapeutics — Proactive Investors CEO Series 2018 on 6ix